Longeveron (NASDAQ:LGVN) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research note released on Wednesday morning, Benzinga reports. They currently have a $10.00 target price on the stock.

Separately, Maxim Group lowered their price target on shares of Longeveron from $15.00 to $6.00 and set a buy rating for the company in a research note on Tuesday, August 27th.

Longeveron Trading Down 8.8 %

Shares of NASDAQ LGVN opened at $1.97 on Wednesday. The stock’s 50-day moving average is $2.70 and its 200 day moving average is $2.66. The stock has a market cap of $12.51 million, a price-to-earnings ratio of -0.20 and a beta of 0.37. Longeveron has a 1-year low of $0.77 and a 1-year high of $26.80.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.80). The business had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $0.53 million. Longeveron had a negative return on equity of 237.57% and a negative net margin of 1,513.83%. On average, analysts forecast that Longeveron will post -3.89 EPS for the current fiscal year.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. Renaissance Technologies LLC bought a new position in Longeveron Inc. (NASDAQ:LGVN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 146,700 shares of the company’s stock, valued at approximately $236,000. Renaissance Technologies LLC owned 2.31% of Longeveron as of its most recent SEC filing. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.